China-based Coherent Biopharma and C-Ray Therapeutics have announced a strategic partnership to delve into the development of peptide-drug conjugates (PDCs), with a particular focus on bispecific-ligand drug conjugates (bi-XDCs). The collaboration aims to leverage the strengths of both companies to advance in this innovative field of drug development. Financial details of the agreement have not been disclosed.
Coherent Bio’s Bi-XDC Development Platform and Pipeline
Coherent Bio boasts a first-in-class Bi-XDC development platform, which is complemented by a robust pipeline of programs targeting global development. The company’s portfolio currently encompasses 3 clinical-stage products that are undergoing 7 concurrent trials in both the US and China. This extensive clinical trial program underscores Coherent Bio’s commitment to advancing PDC technology and bringing new treatment options to patients worldwide.
C-Ray Therapeutics’ Expertise in Radiopharmaceuticals
C-Ray Therapeutics specializes in radiochemistry and the application of nuclear technology, bolstered by strong academic medical and scientific capabilities. The company’s aspiration to become a leading radiopharmaceuticals platform company in China aligns with the growing global demand for targeted radiopharmaceutical therapies.
The Synergy of the Partnership
The partnership between Coherent Biopharma and C-Ray Therapeutics is set to combine Coherent Bio’s Bi-XDC development expertise with C-Ray’s radiopharmaceutical capabilities, creating a synergistic collaboration that could lead to breakthroughs in the development of novel cancer treatments. This alliance highlights the potential for Chinese biopharmaceutical companies to make significant contributions to the global healthcare landscape through innovative drug conjugate technologies.-Fineline Info & Tech
